{
    "clinical_study": {
        "@rank": "33704", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give L-743,872 to\n      patients with thrush, an AIDS-related yeast infection of the mouth, that has not been cured\n      with fluconazole treatment."
        }, 
        "brief_title": "Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole", 
        "condition": [
            "Candidiasis, Oral", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Candidiasis", 
                "Candidiasis, Oral"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to treatment with L-743,872 at one of two doses administered\n      intravenously by a peripheral line once-daily. Patients are treated for 48 hours beyond\n      resolution of symptoms or for a maximum of 14 days. Each patient is expected to complete the\n      study, including the 14-day follow-up, within approximately 4 weeks. A physical examination\n      is performed daily during the antifungal treatment period and at the follow-up visits 7 and\n      14 days post-therapy. Laboratory tests of blood and urine for safety are performed every\n      three days during treatment and at follow-up 7 days post-therapy. Liver enzymes are drawn at\n      the 14-day follow-up visit."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        You may be eligible for this study if you:\n\n          -  Have thrush that has not responded to fluconazole treatment.\n\n          -  Are 18-65 years old."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "70", 
        "firstreceived_date": "June 19, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005920", 
            "org_study_id": "267B", 
            "secondary_id": "012-00"
        }, 
        "intervention": {
            "intervention_name": "L-743,872", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Fluconazole", 
                "Caspofungin"
            ]
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Dose-Response Relationship, Drug", 
            "Fluconazole", 
            "Antifungal Agents", 
            "Candidiasis, Oral", 
            "Pharyngeal Diseases", 
            "MK 0991"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rahway", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07065"
                }, 
                "name": "Carol Sable"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multiclinic, Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety, Tolerability, and Efficacy of L-743,872 in the Treatment of Fluconazole-Unresponsive Oropharyngeal Candidiasis in Adults", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005920"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2000"
    }, 
    "geocoordinates": {
        "Carol Sable": "40.608 -74.278"
    }
}